Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
The global Carbocisteine API market size was valued at USD 63.03 Million in 2022 and will reach USD 85.44 Million in 2028, with a CAGR of 5.2% during 2022-2028.
Carbocisteine is a type of drug called a mucolytic that reduces the viscosity of sputum, so it can be used to relieve symptoms of chronic obstructive pulmonary disease and bronchiectasis, making it easier for patients to cough up sputum. Carbocisteine API is the active ingredient in the drug.
From the perspective of production, for the Carbocisteine API industry, the epidemic has had an impact on the production plans of companies in the Carbocisteine API industry. Due to the outbreak of COVID-19, the supply of raw materials has been affected. For example, manufacturing plants such as L-cysteine hydrochloride and Chloroacetic acid have suspended production plans, and the supply of raw materials in the market has decreased. Due to the traffic control caused by the epidemic, the transportation of raw materials will also be blocked. All of these could lead to disruptions in the supply of raw materials for the Carbocisteine API industry, thereby affecting the company's production plans. On the other hand, due to the impact of the new crown pneumonia epidemic, in order to prevent the further spread of the epidemic, the government issued travel restrictions and related isolation policies, which reduced the management efficiency of enterprises in the industry and also affected the company's production plan.
From the perspective of downstream demand, the downstream customers of Carbocisteine API are mainly pharmaceutical companies. However, due to the outbreak, pharmaceutical companies have put their manufacturing activities on hold due to disruptions in raw materials and labor, as well as government regulations. As a result, there is less demand for Carbocisteine APIs from pharmaceutical companies. In addition, due to the impact of the epidemic on logistics, many countries have imposed controls on domestic transportation and the movement of people, and imposed restrictions on goods. This has resulted in varying degrees of logistical disruption, cargo accumulation and shipping delays during the sale of Carbocisteine API. As a result, sales of Carbocisteine API also took a hit. In general, the outbreak of the epidemic has had a negative impact on industry companies.
Side Effects of Carbocisteine Drugs
Carbocisteine drugs have the possibility of causing gastrointestinal bleeding and are contraindicated in active peptic ulcers. At the same time, you should avoid taking strong antitussives at the same time as taking this drug, so as not to block the airway with phlegm. During use, patients occasionally experienced adverse reactions such as mild dizziness, nausea, stomach discomfort, diarrhea, gastrointestinal bleeding, and skin rash. The side effects of the drug Carbocisteine are one reason that restrains the industry.
Continuously increase R&D investment
At present, the form of economic development is relatively severe, which brings a lot of pressure to the development of some Carbocisteine API enterprises. Under heavy pressure, some Carbocisteine API companies have begun to use various methods to improve their competitiveness. If industry companies cannot maintain their leading edge in technological innovation, new product development and cost control, the company's products face the risk of declining product gross profit margins. To this end, companies in the Carbocisteine API industry need to further innovate in R&D and increase investment in R&D, accelerate new product upgrade iterations and achieve product differentiation, and always maintain product leadership in the market. In general, with the continuous development of the Carbocisteine API industry market, the market has become increasingly tense, and Carbocisteine API companies have begun to increase their R&D investment in the optimization of the synthesis process of Carbocisteine API. Continuously increasing investment in R&D will be one of the opportunities for industry development.
Region Overview:
In 2022, the share of the Carbocisteine API market in China stood at 48.25%.
Company Overview:
Wuhan Grand Hoyo is one of the major players operating in the Carbocisteine API market, holding a share of 27.88% in 2022.
Wuhan Grand Hoyo
Wuhan Grand Hoyo is based on the research and development and production of amino acids and their derivatives, and is committed to the high-tech industrialization in the field of biomedicine, relying on the achievements of the School of Life Sciences of Wuhan University and the Hubei Provincial Amino Acid Engineering Technology Research Center. The company has a rigorous quality assurance system and has passed ISO 9001, HACCP, FSSC22000, SC quality management system certification, China GMP certification, South Korea KDMF certification, EU EUGMP certification, EU EDQM COS certification, and KOSHER and HALAL certification. The company now has a number of production approvals for APIs such as acetyl tyrosine, acetylcysteine, cysteine hydrochloride, carbocisteine, arginine hydrochloride, histidine hydrochloride, and lysine hydrochloride.
Moehs Iberica
Moehs Iberica has a long tradition and experience in the manufacture of active pharmaceutical and veterinary ingredients, agrochemicals, nutraceuticals, cosmetics and general fine chemicals. The company has a high level of quality and safety standards GMP and ICH.
Application Overview:
The Long-Term Respiratory Diseases segment by application is expected to continue its dominance over the forecast period from 2022 to 2027, taking up a market share of 94.4% in 2027.
The Carbocisteine API market report covers sufficient and comprehensive data on market introduction, segmentations, status and trends, opportunities and challenges, industry chain, competitive analysis, company profiles, and trade statistics, etc. It provides in-depth and all-scale analysis of each segment of types, applications, players, 5 major regions and sub-division of major countries, and sometimes end user, channel, technology, as well as other information individually tailored before order confirmation.
Meticulous research and analysis were conducted during the preparation process of the report. The qualitative and quantitative data were gained and verified through primary and secondary sources, which include but not limited to Magazines, Press Releases, Paid Databases, Maia Data Center, National Customs, Annual Reports, Public Databases, Expert interviews, etc. Besides, primary sources include extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs, and marketing executives, downstream distributors, as well as end-clients.
In this report, the historical period starts from 2018 to 2022, and the forecast period ranges from 2023 to 2028. The facts and data are demonstrated by tables, graphs, pie charts, and other pictorial representations, which enhances the effective visual representation and decision-making capabilities for business strategy.
Key Companies in the global Carbocisteine API market covered in Chapter 4:
BCF Life Sciences
Afton Pharma
Huaheng Biologgical Technology
Ningbo Haishuo Biotechnology Co.,Ltd
Wuhan Grand Hoyo
Yunpeng Pharmaceutical
Moehs Iberica
In Chapter 12 and Chapter 14.1, on the basis of types, the Carbocisteine API market from 2018 to 2028 is primarily split into:
Type 1
Type 2
In Chapter 13 and Chapter 14.2, on the basis of the Downstream Industry, the Carbocisteine API market from 2018 to 2028 covers:
Long-Term Respiratory Diseases
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, history and forecast (2018-2028) of the following regions are covered in Chapters 6, 7, 8, 9, 10, 11, 15:
North America (United States, Canada, Mexico)
Europe (Germany, United Kingdom, France, Italy, Spain)
Asia Pacific (China, Japan, South Korea, India, Southeast Asia)
South America (Brazil, Argentina)
Middle East & Africa (Saudi Arabia, UAE, South Africa)
Outline:
Chapter 1 begins with the Carbocisteine API market scope and definition, product segment introduction, global overall market size, as well as market dynamics scenarios such as opportunities, challenges, and industry development trends under inflation. It offers a high-level view of the current state of the Carbocisteine API market and its likely evolution in the short to mid-term and long term.
Chapter 2 provides Carbocisteine API industry chain analysis, covering raw materials analysis, cost structure, price estimate, and forecast, along with price-impacting factors, downstream channels, and major customers. It aims to help readers to grab insights into product upstream, midstream, and downstream fields.
Chapter 3 depicts Carbocisteine API industry competitive analysis regarding market concentration rate, saturation rate, feasibility analysis from new entrants, as well as substitute's status and trends. It indicates the developing space and prospects of the current industry.
Chapter 4 analyzes extensive company profiles, comprising company basic info, product or service profiles, and sales, price, value, gross, and gross margin 2018-2023. It incorporates the Carbocisteine API market ranking, benchmarks, and company business portfolio.
Chapter 5 presents trade statistics of import and export volume from 2018-2023, demonstrating domestic and international market comparisons in specific countries.
Chapters 6-10 highlight Carbocisteine API market status at the regional and country levels, including 5 major regions of North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. The region and country list in the sample is only for reference, and it can be adjusted as required.
Chapter 11 involves geographical market figures of sales, value, market share, and growth rate. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of each specific region.
Chapters 12-13 evaluate the Carbocisteine API market based on different types and applications. It focuses on sales and value of 2018-2023 from both vertical and horizontal perspectives.
Chapters 14-15 elaborate on the Carbocisteine API market forecast data from 2023-2028, segmented by types and applications, regions, and major countries, helping readers to know future aspects and growth trends.
Chapter 16 ends with an elaboration of data sources and research methodology. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
2022
Carbocisteine is a type of drug called a mucolytic that reduces the viscosity of sputum, so it can be used to relieve symptoms of chronic obstructive pulmonary disease and bronchiectasis, making it easier for patients to cough up sputum. Carbocisteine API is the active ingredient in the drug.
From the perspective of production, for the Carbocisteine API industry, the epidemic has had an impact on the production plans of companies in the Carbocisteine API industry. Due to the outbreak of COVID-19, the supply of raw materials has been affected. For example, manufacturing plants such as L-cysteine hydrochloride and Chloroacetic acid have suspended production plans, and the supply of raw materials in the market has decreased. Due to the traffic control caused by the epidemic, the transportation of raw materials will also be blocked. All of these could lead to disruptions in the supply of raw materials for the Carbocisteine API industry, thereby affecting the company's production plans. On the other hand, due to the impact of the new crown pneumonia epidemic, in order to prevent the further spread of the epidemic, the government issued travel restrictions and related isolation policies, which reduced the management efficiency of enterprises in the industry and also affected the company's production plan.
From the perspective of downstream demand, the downstream customers of Carbocisteine API are mainly pharmaceutical companies. However, due to the outbreak, pharmaceutical companies have put their manufacturing activities on hold due to disruptions in raw materials and labor, as well as government regulations. As a result, there is less demand for Carbocisteine APIs from pharmaceutical companies. In addition, due to the impact of the epidemic on logistics, many countries have imposed controls on domestic transportation and the movement of people, and imposed restrictions on goods. This has resulted in varying degrees of logistical disruption, cargo accumulation and shipping delays during the sale of Carbocisteine API. As a result, sales of Carbocisteine API also took a hit. In general, the outbreak of the epidemic has had a negative impact on industry companies.
Side Effects of Carbocisteine Drugs
Carbocisteine drugs have the possibility of causing gastrointestinal bleeding and are contraindicated in active peptic ulcers. At the same time, you should avoid taking strong antitussives at the same time as taking this drug, so as not to block the airway with phlegm. During use, patients occasionally experienced adverse reactions such as mild dizziness, nausea, stomach discomfort, diarrhea, gastrointestinal bleeding, and skin rash. The side effects of the drug Carbocisteine are one reason that restrains the industry.
Continuously increase R&D investment
At present, the form of economic development is relatively severe, which brings a lot of pressure to the development of some Carbocisteine API enterprises. Under heavy pressure, some Carbocisteine API companies have begun to use various methods to improve their competitiveness. If industry companies cannot maintain their leading edge in technological innovation, new product development and cost control, the company's products face the risk of declining product gross profit margins. To this end, companies in the Carbocisteine API industry need to further innovate in R&D and increase investment in R&D, accelerate new product upgrade iterations and achieve product differentiation, and always maintain product leadership in the market. In general, with the continuous development of the Carbocisteine API industry market, the market has become increasingly tense, and Carbocisteine API companies have begun to increase their R&D investment in the optimization of the synthesis process of Carbocisteine API. Continuously increasing investment in R&D will be one of the opportunities for industry development.
Region Overview:
In 2022, the share of the Carbocisteine API market in China stood at 48.25%.
Company Overview:
Wuhan Grand Hoyo is one of the major players operating in the Carbocisteine API market, holding a share of 27.88% in 2022.
Wuhan Grand Hoyo
Wuhan Grand Hoyo is based on the research and development and production of amino acids and their derivatives, and is committed to the high-tech industrialization in the field of biomedicine, relying on the achievements of the School of Life Sciences of Wuhan University and the Hubei Provincial Amino Acid Engineering Technology Research Center. The company has a rigorous quality assurance system and has passed ISO 9001, HACCP, FSSC22000, SC quality management system certification, China GMP certification, South Korea KDMF certification, EU EUGMP certification, EU EDQM COS certification, and KOSHER and HALAL certification. The company now has a number of production approvals for APIs such as acetyl tyrosine, acetylcysteine, cysteine hydrochloride, carbocisteine, arginine hydrochloride, histidine hydrochloride, and lysine hydrochloride.
Moehs Iberica
Moehs Iberica has a long tradition and experience in the manufacture of active pharmaceutical and veterinary ingredients, agrochemicals, nutraceuticals, cosmetics and general fine chemicals. The company has a high level of quality and safety standards GMP and ICH.
Application Overview:
The Long-Term Respiratory Diseases segment by application is expected to continue its dominance over the forecast period from 2022 to 2027, taking up a market share of 94.4% in 2027.
The Carbocisteine API market report covers sufficient and comprehensive data on market introduction, segmentations, status and trends, opportunities and challenges, industry chain, competitive analysis, company profiles, and trade statistics, etc. It provides in-depth and all-scale analysis of each segment of types, applications, players, 5 major regions and sub-division of major countries, and sometimes end user, channel, technology, as well as other information individually tailored before order confirmation.
Meticulous research and analysis were conducted during the preparation process of the report. The qualitative and quantitative data were gained and verified through primary and secondary sources, which include but not limited to Magazines, Press Releases, Paid Databases, Maia Data Center, National Customs, Annual Reports, Public Databases, Expert interviews, etc. Besides, primary sources include extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs, and marketing executives, downstream distributors, as well as end-clients.
In this report, the historical period starts from 2018 to 2022, and the forecast period ranges from 2023 to 2028. The facts and data are demonstrated by tables, graphs, pie charts, and other pictorial representations, which enhances the effective visual representation and decision-making capabilities for business strategy.
Key Companies in the global Carbocisteine API market covered in Chapter 4:
BCF Life Sciences
Afton Pharma
Huaheng Biologgical Technology
Ningbo Haishuo Biotechnology Co.,Ltd
Wuhan Grand Hoyo
Yunpeng Pharmaceutical
Moehs Iberica
In Chapter 12 and Chapter 14.1, on the basis of types, the Carbocisteine API market from 2018 to 2028 is primarily split into:
Type 1
Type 2
In Chapter 13 and Chapter 14.2, on the basis of the Downstream Industry, the Carbocisteine API market from 2018 to 2028 covers:
Long-Term Respiratory Diseases
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, history and forecast (2018-2028) of the following regions are covered in Chapters 6, 7, 8, 9, 10, 11, 15:
North America (United States, Canada, Mexico)
Europe (Germany, United Kingdom, France, Italy, Spain)
Asia Pacific (China, Japan, South Korea, India, Southeast Asia)
South America (Brazil, Argentina)
Middle East & Africa (Saudi Arabia, UAE, South Africa)
Outline:
Chapter 1 begins with the Carbocisteine API market scope and definition, product segment introduction, global overall market size, as well as market dynamics scenarios such as opportunities, challenges, and industry development trends under inflation. It offers a high-level view of the current state of the Carbocisteine API market and its likely evolution in the short to mid-term and long term.
Chapter 2 provides Carbocisteine API industry chain analysis, covering raw materials analysis, cost structure, price estimate, and forecast, along with price-impacting factors, downstream channels, and major customers. It aims to help readers to grab insights into product upstream, midstream, and downstream fields.
Chapter 3 depicts Carbocisteine API industry competitive analysis regarding market concentration rate, saturation rate, feasibility analysis from new entrants, as well as substitute's status and trends. It indicates the developing space and prospects of the current industry.
Chapter 4 analyzes extensive company profiles, comprising company basic info, product or service profiles, and sales, price, value, gross, and gross margin 2018-2023. It incorporates the Carbocisteine API market ranking, benchmarks, and company business portfolio.
Chapter 5 presents trade statistics of import and export volume from 2018-2023, demonstrating domestic and international market comparisons in specific countries.
Chapters 6-10 highlight Carbocisteine API market status at the regional and country levels, including 5 major regions of North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. The region and country list in the sample is only for reference, and it can be adjusted as required.
Chapter 11 involves geographical market figures of sales, value, market share, and growth rate. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of each specific region.
Chapters 12-13 evaluate the Carbocisteine API market based on different types and applications. It focuses on sales and value of 2018-2023 from both vertical and horizontal perspectives.
Chapters 14-15 elaborate on the Carbocisteine API market forecast data from 2023-2028, segmented by types and applications, regions, and major countries, helping readers to know future aspects and growth trends.
Chapter 16 ends with an elaboration of data sources and research methodology. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Years considered for this report:
Historical Years:
2018-2022Base Year:
2022Estimated Year:
2023Forecast Period:
2023-2028Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
